Trovagene Advances Pushing Company Toward Forefront of New and Highly-Profitable Technology

Aug. 24, 2012 - PRLog -- SAN DIEGO – Trovagene, Inc., a developer of transrenal molecular diagnostics, was buoyed by two biotech reports examining the company’s advances in non-invasive testing with urine samples replacing blood in finding and monitoring cancer and other conditions.

“Over time, transrenal testing could eventually replace traditional blood tests,” wrote financial consultant Chris French in a report on August 22 for “Investment Underground,” an online site providing commodities and stock market news and trends. “This could propel Trovagene to the forefront of a new technology and prove very profitable over time.”

Noting that the company reported a loss it the second quarter of 2012, French observed, “with numerous patents, partnerships and the ability to provide testing services with the potential to change the way diseases and other conditions are diagnosed, investors should remain positive that the company will turn a profit.”

The full report may be found at: http://investmentunderground.com/5819/featured/trovagene-...

In another analysis, BioMedReports.com Contributor A. J. Deniken wrote that in the cancer research community, one of the most prevalent discussions is gene mutation detection in cancer patients. “Trovagene is positioned to become a leader in this area,” Deniken said. He also noted that Trovagene has brought down the cost of detecting DNA fragments through readily available digital PCR Assays. As a result, he concludes, “These technology and cost advances, along with the ability to use urine samples in several high volume markets, make Trovagene’s technology a potential market changer.”

Trovagene  has had “a productive year,” Deniken wrote in the July 17 article, “but much of this success has not been reflected in their stock price.” He said his analysis showed the company is “moving quickly to develop and study additional assays for various cancers...The revenue potential of Trovagene‘s platform in the cancer monitoring market alone is strong.”

BioMedReports.Com covers Wall Street’s biomedical sector and provides financial and investment intelligence to investors. Deniken’s full report may be found at:

http://finance.yahoo.com/news/trovagene-may-solved-elusiv...

Headquartered in San Diego, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.  The clinical utility of oncogene mutation is broadly recognized.  Trovagene is leveraging its intellectual property in oncogene mutations via out-licensing and use of its transrenal technologies to extend oncogene mutation detection using urine as a sample.  As a non-invasive and abundant sample, urine can overcome many of the cost and collection challenges presented by biopsy, as well as the volume limitations of blood.

For further information, contact:

Alex Michelini

michelinialex@aol.com.

The Promotion Factory

5 E. 19th Street

New York, NY 10003

T. 212-217-9065